Workflow
2 Beaten-Down Stocks to Buy on the Dip
CRSPCRISPR Therapeutics(CRSP) The Motley Fool·2025-03-22 20:04

Group 1: CRISPR Therapeutics - CRISPR Therapeutics' shares have declined by 41% over the past year, primarily due to slow revenue generation from its approved gene-editing therapy, Casgevy, which treats rare blood diseases [2][3] - Casgevy is priced at 2.2millionpertreatmentandisaone−timecurativeoption,withasignificantmarketopportunityintheU.S.,U.K.,EuropeanUnion,andseveralMiddleEasterncountries[5][4]−Thecompanyisalsodevelopingothergene−editingtherapies,includingafunctionalcurefortype1diabetesandCTX112forB−cellmalignancies,whichhasreceivedRegenerativeMedicineAdvancedTherapydesignation[6][7]Group2:Merck−Merck′srevenueforthelastyearwas2.2 million per treatment and is a one-time curative option, with a significant market opportunity in the U.S., U.K., European Union, and several Middle Eastern countries [5][4] - The company is also developing other gene-editing therapies, including a functional cure for type 1 diabetes and CTX112 for B-cell malignancies, which has received Regenerative Medicine Advanced Therapy designation [6][7] Group 2: Merck - Merck's revenue for the last year was 64.2 billion, a 7% increase from 2023, with Keytruda generating $29.5 billion, accounting for approximately 46% of total revenue [9][12] - Competition from ivonescimab, which performed better than Keytruda in a clinical trial, poses a risk to Keytruda's market share, especially as its patent will expire in 2028 [8][9] - Merck is proactively extending Keytruda's patent life and developing new medicines, including LM-299 and HS-10535, while maintaining a strong dividend yield of over 3.4% [10][11][12]